Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermasorb HC + Dermasorb TA is a topical combination regimen consisting of two medium-to-low potency corticosteroid products, hydrocortisone (Dermasorb HC) and triamcinolone acetonide (Dermasorb TA), supplied in emollient or cleanser-based vehicles for dermatologic use. Hydrocortisone and triamcinolone are synthetic glucocorticoid corticosteroids that bind to the cytosolic glucocorticoid receptor in skin cells, modulating gene transcription to suppress production of pro‑inflammatory cytokines, reduce vasodilation and capillary permeability, and inhibit local immune and allergic responses, thereby decreasing erythema, edema, pruritus, and irritation in inflammatory dermatoses. The combination may be used to tailor anti‑inflammatory potency and vehicle type across different body areas or disease severity, for conditions such as eczema, dermatitis, allergic rashes, and other corticosteroid‑responsive skin disorders.[2][5][8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dermasorb HC + Dermasorb TA.